Your search history is turned on.
Date: April 18, 2024 Jurisdictions: Alberta, British Columbia, Ontario
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced th...
Date: April 16, 2024 Jurisdictions: Alberta, British Columbia, Ontario
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Vancouver, British Columbia--(Newsfile Corp. - April 16, 2024) - InMed Pharmaceuticals ...
Date: April 4, 2024 Jurisdictions: Alberta, British Columbia, Ontario
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathway In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function Molecular analysis data further explains prev...
Date: March 20, 2024 Jurisdictions: Alberta, British Columbia, Ontario
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that it has received a notification letter from the Li...
Date: February 13, 2024 Jurisdictions: Alberta, British Columbia, Ontario
f10q1223_inmedpharma_AsFiled.pdf Exhibit 31.2 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jonathan Tegge, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of InMed Pharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact ...
f10q1223_inmedpharma_AsFiled.pdf Exhibit 31.1 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Eric A. Adams, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of InMed Pharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact n...
f10q1223_inmedpharma_AsFiled.pdf ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. InMed Pharmaceuticals Inc. MANAGEMENTS DISCUSSION AND ANALYSIS Three and six months ended December 31, 2023 InMed Pharmaceuticals Inc. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS Three and Si...
f10q1223_inmedpharma_AsFiled.pdf PART I ITEM 1. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS. Unaudited Condensed Consolidated Interim Financial Statements of InMed Pharmaceuticals Inc. For the Three and Six Months Ended December 31, 2023 and 2022 Suite 310 815 West Hastings Street Vancouver, BC, Canada, V6C 1B4 Tel: +1-604-669-7207 1 I...
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update Advancing two new preclinical programs in Alzheimer's and Age-Related Macular Degeneration Closed calendar year 2023 with cash position of US$9.5 million 164% revenue growth in the commercial BayMedica subsidiary Vancouver, British Columbia--(Newsfile Corp. - February 13, 2024) - InMed Pharmaceuticals Inc...
Date: February 9, 2024 Jurisdictions: Alberta, British Columbia, Ontario
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Spec...